Deadline: 06-Aug-21
Gilead Sciences Pty Ltd is proud to work in partnership with the Australian research and clinical community to provide opportunities for investigation and research in HIV, chronic viral hepatitis, haematological malignancies, solid tumours, and invasive fungal infections by establishing the Gilead Australia Fellowship: Research Grants Program, an Australian-specific initiative enabling researchers to apply for funding support for innovative projects with a clinical but ‘real-world’ focus.
Aim and Scope
Gilead is committed to supporting innovative local research initiatives to improve patient outcomes. The Research Grants Program enables Australian researchers to apply for funding across a range of therapeutic areas.
The Program aims to support:
- projects with a clinical and ‘real-world’ focus
- the development and implementation of best practice to enhance patient outcomes
- research in the specific disease areas of HIV and/or chronic viral hepatitis, haematological malignancies, solid tumours, and invasive fungal infections.
Themes
Research proposals are invited that explore and address the following issues and themes:
- HIV/chronic viral hepatitis
- Developing and/or evaluating novel ways to prevent new HIV and/or chronic viral hepatitis infections
- Improving community, carceral system, primary and secondary care awareness, interest and uptake of screening to identify undiagnosed people living with HIV and/or chronic viral hepatitis in high prevalence and/or under served populations
- Reducing late diagnosis of HIV and/or chronic viral hepatitis in high prevalence and/or under-served populations
- Improving access, uptake and adherence to medication for HIV and/or chronic viral hepatitis, with emphasis on marginalised and/or under-served populations such as Indigenous communities, drug users and immigrants
- Identifying the reasons for and strategies to reduce people living with HIV and/or chronic viral hepatitis being lost to follow-up
- Haematological malignancies
- Improving care and outcomes of people living with lymphoma and/or leukaemia
- Solid tumours
- Improving the care and outcomes of people living with metastatic breast cancer
- Invasive fungal infection
- Improving patient care, quality and safety by investigating:
- antifungal resistance
- breakthrough fungal infections, including incidence, risk factors, populations at risk and management strategies
- optimisation of antifungal use and prevention of unnecessary exposure
- appropriate sequencing of antifungals.
- Improving patient care, quality and safety by investigating:
Funding Information
- The total funding available for the 2022 Research Grants Program is $300,000.
- The requested level of funding should be stated at the time of application.*
- Funding is contingent on the project:
- being granted ethics approval (if required)
- concluding in no more than 18 months after execution of agreement.
- *A maximum award for successful proposals will be $60k. The exact amount of funding allocated to each project may vary depending on the nature of the project. Funding is entirely independent of the use of any particular therapeutic agent.
- Projects should run during the calendar year (January–December) of 2022 and all projects must be completed by July 2023.
What Projects Will Be Considered For Funding?
- Financial grants will be awarded on a competitive basis to individuals, organisations or groups of healthcare providers within a locality whose proposals are focused on investigating solutions to improve care for people living with HIV and/or chronic viral hepatitis, haematological malignancies, solid tumours, and invasive fungal infections. This includes clinical and academic staff at Australian hospitals, clinics, universities and research institutes, young investigators, nurses, GPs and other healthcare providers/researchers from professional organisations, in both urban and rural areas.
- Applications for community based projects that may not necessarily fall under traditional research grant criteria are welcome. In addition, projects may be based on sociological and epidemiological aspects of patient care in these three therapy areas, as well as practical aspects. A key focus for the judges is innovation, with projects driven by novel approaches particularly sought.
For more information, visit https://gileadfellowship.com.au/Guidance
